Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series.

@article{Ferreiro2014EverolimusbasedII,
  title={Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series.},
  author={A. Otero Ferreiro and M. de los Angeles V{\'a}zquez-Mill{\'a}n and Fernando Sanchez Lopez and Manuel G{\'o}mez Guti{\'e}rrez and Sonia P{\'e}rtega D{\'i}az and Marcia Pati{\~n}o},
  journal={Transplantation proceedings},
  year={2014},
  volume={46 10},
  pages={3496-501}
}
BACKGROUND Liver transplantation offers the most effective treatment in patients with hepatocellular carcinoma (HCC). However, transplant patients outside the Milan criteria have a high risk of tumor recurrence, which has been linked to standard immunosuppression regimens. Everolimus is a mammalian target of rapamycin inhibitor that has been used for immunosuppression, but its effect on recurrence and survival in HCC patients with a high risk of tumor recurrence has not been examined. We… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS